Proactive versus Rank-Down Topical Corticosteroid Therapy for Maintenance of Remission in Pediatric Atopic Dermatitis: A Randomized, Open-Label, Active-Controlled, Parallel-Group Study (Anticipate Study)

被引:4
|
作者
Kamiya, Koji [1 ]
Saeki, Hidehisa [2 ]
Tokura, Yoshiki [3 ,4 ]
Yoshihara, Shigemi [5 ]
Sugai, Junichi [6 ]
Ohtsuki, Mamitaro [1 ]
机构
[1] Jichi Med Univ, Dept Dermatol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[2] Nippon Med Sch, Dept Dermatol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
[3] Chutoen Gen Med Ctr, Allerg Dis Res Ctr, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[4] Chutoen Gen Med Ctr, Dept Dermatol & Skin Oncol, 1-1 Shobugaike, Kakegawa, Shizuoka 4368555, Japan
[5] Dokkyo Med Univ, Dept Pediat, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
[6] Sugai Dermatol Parkside Clin, 6-7-7 Motoimaizumi, Utsunomiya, Tochigi 3210954, Japan
关键词
atopic dermatitis; pediatric; proactive therapy; rank-down therapy; topical corticosteroids; FLUTICASONE PROPIONATE CREAM; DOUBLE-BLIND; GUIDELINES; MANAGEMENT; RELAPSE; EMOLLIENT; CHILDREN; MODERATE; RISK; 0.05-PERCENT;
D O I
10.3390/jcm11216477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topical corticosteroids are used as first-line treatment for atopic dermatitis (AD). Regarding the maintenance of remission achieved by topical corticosteroids, no previous studies have compared proactive therapy with rank-down therapy. We compared their efficacy and safety in Japanese children with moderate to severe AD. Patients who had achieved remission with a very strong topical corticosteroid were randomized to 4-week maintenance treatment with either intermittent use of the same drug (proactive therapy) or daily use of a strong topical corticosteroid for 1 week followed by daily use of a medium-potency topical corticosteroid for 3 weeks (rank-down therapy); 49 patients were randomized (proactive therapy, n = 24; rank-down therapy, n = 25). During maintenance treatment, the relapse rate was 8.33% in the proactive therapy group and 20.0% in the rank-down therapy group (p = 0.0859). The mean (+/- standard deviation) itching score on a numerical rating scale in the rank-down therapy group increased significantly from 2.5 +/- 1.9 to 3.6 +/- 2.6 (p = 0.0438). Adverse events occurred in 2 patients receiving proactive therapy and 3 patients receiving rank-down therapy. Proactive therapy appears to be as safe as rank-down therapy and may be more effective for itch in pediatric AD in remission.
引用
收藏
页数:11
相关论文
共 45 条
  • [41] Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
    Shimizu, Toshimasa
    Kawashiri, Shin-ya
    Morimoto, Shimpei
    Kawazoe, Yurika
    Kuroda, Shohei
    Kawasaki, Rina
    Ito, Yasuko
    Kiya, Rieko
    Sato, Shuntaro
    Yamamoto, Hiroshi
    Kawakami, Atsushi
    TRIALS, 2023, 24 (01)
  • [42] Comparison of the Pharmacokinetics of a New 15-mg Modified-Release Tablet Formulation of Metoclopramide Versus a 10-mg Immediate-Release Tablet: A Single- and Multiple-Dose, Randomized, Open-Label, Parallel-Group Study in Healthy Mexican Male Volunteers
    Bernardo-Escudero, Roberto
    Alonso-Campero, Rosalba
    de Jesus Francisco-Doce, Maria Teresa
    Cortes-Fuentes, Myriam
    Villa-Vargas, Miriam
    Angeles-Uribe, Juan
    CLINICAL THERAPEUTICS, 2011, 33 (05) : 630 - 643
  • [43] Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804)
    Zhao, Hongyun
    Fan, Yun
    Ma, Shenglin
    Song, Xiangqun
    Han, Baohui
    Cheng, Ying
    Huang, Cheng
    Yang, Shujun
    Liu, Xiaoqing
    Liu, Yunpeng
    Lu, Shun
    Wang, Jie
    Zhang, Shucai
    Zhou, Caicun
    Wang, Mengzhao
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 655 - 664
  • [44] Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial
    Backeljauw, Philippe F.
    Miller, Bradley S.
    Dutailly, Pascale
    Houchard, Aude
    Lawson, Elizabeth
    Hale, Daniel E.
    Reiner, Barry
    Sperling, Mark A.
    HORMONE RESEARCH IN PAEDIATRICS, 2015, 83 (04): : 268 - 279
  • [45] Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
    Iwamoto, Naoki
    Chiba, Ko
    Sato, Shuntaro
    Shiraishi, Kazuteru
    Watanabe, Kounosuke
    Oki, Nozomi
    Okada, Akitomo
    Koga, Tomohiro
    Kawashiri, Shin-ya
    Tamai, Mami
    Hosogaya, Naoki
    Furuyama, Masako
    Kobayashi, Makiko
    Saito, Kengo
    Okubo, Naoki
    Uetani, Masataka
    Osaki, Makoto
    Kawakami, Atsushi
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)